nodes	percent_of_prediction	percent_of_DWPC	metapath
Amphetamine—CYP2A6—lung cancer	0.5	1	CbGaD
Amphetamine—SLC22A3—Irinotecan—lung cancer	0.0874	0.535	CbGbCtD
Amphetamine—CYP2D6—Gefitinib—lung cancer	0.0243	0.149	CbGbCtD
Amphetamine—CYP2D6—Vinorelbine—lung cancer	0.0187	0.115	CbGbCtD
Amphetamine—CYP2D6—Erlotinib—lung cancer	0.0144	0.0879	CbGbCtD
Amphetamine—CYP2D6—Vinblastine—lung cancer	0.0115	0.0706	CbGbCtD
Amphetamine—CYP2D6—Doxorubicin—lung cancer	0.00709	0.0434	CbGbCtD
Amphetamine—TAAR1—respiratory system—lung cancer	0.00402	0.173	CbGeAlD
Amphetamine—TAAR1—lung—lung cancer	0.00213	0.092	CbGeAlD
Amphetamine—CARTPT—lymph node—lung cancer	0.00146	0.063	CbGeAlD
Amphetamine—SLC22A5—mammary gland—lung cancer	0.00106	0.0458	CbGeAlD
Amphetamine—SLC6A3—respiratory system—lung cancer	0.00103	0.0446	CbGeAlD
Amphetamine—Pseudoephedrine—IL2—lung cancer	0.00101	0.294	CrCbGaD
Amphetamine—SLC6A4—respiratory system—lung cancer	0.000946	0.0408	CbGeAlD
Amphetamine—MAOB—respiratory system—lung cancer	0.0009	0.0388	CbGeAlD
Amphetamine—SLC6A2—respiratory system—lung cancer	0.000833	0.0359	CbGeAlD
Amphetamine—DRD2—respiratory system—lung cancer	0.000759	0.0328	CbGeAlD
Amphetamine—MAOB—bronchus—lung cancer	0.000741	0.0319	CbGeAlD
Amphetamine—SLC18A2—lung—lung cancer	0.000725	0.0313	CbGeAlD
Amphetamine—SLC22A5—respiratory system—lung cancer	0.000707	0.0305	CbGeAlD
Amphetamine—CYP2A6—lung—lung cancer	0.000647	0.0279	CbGeAlD
Amphetamine—MAOB—cardiac atrium—lung cancer	0.000625	0.0269	CbGeAlD
Amphetamine—SLC22A5—bronchus—lung cancer	0.000582	0.0251	CbGeAlD
Amphetamine—SLC6A3—lung—lung cancer	0.000548	0.0237	CbGeAlD
Amphetamine—SLC22A5—trachea—lung cancer	0.000522	0.0225	CbGeAlD
Amphetamine—SLC22A3—lung—lung cancer	0.000516	0.0223	CbGeAlD
Amphetamine—SLC6A4—lung—lung cancer	0.000503	0.0217	CbGeAlD
Amphetamine—SLC18A2—lymph node—lung cancer	0.000496	0.0214	CbGeAlD
Amphetamine—SLC22A5—cardiac atrium—lung cancer	0.000491	0.0212	CbGeAlD
Amphetamine—MAOB—lung—lung cancer	0.000478	0.0206	CbGeAlD
Amphetamine—Tranylcypromine—CYP2A6—lung cancer	0.000463	0.135	CrCbGaD
Amphetamine—SLC6A2—lung—lung cancer	0.000442	0.0191	CbGeAlD
Amphetamine—DRD2—lung—lung cancer	0.000403	0.0174	CbGeAlD
Amphetamine—SLC22A5—lung—lung cancer	0.000375	0.0162	CbGeAlD
Amphetamine—Selegiline—CYP2A6—lung cancer	0.000359	0.105	CrCbGaD
Amphetamine—SLC22A3—lymph node—lung cancer	0.000353	0.0152	CbGeAlD
Amphetamine—Tranylcypromine—CYP2E1—lung cancer	0.000329	0.0961	CrCbGaD
Amphetamine—MAOB—lymph node—lung cancer	0.000327	0.0141	CbGeAlD
Amphetamine—SLC6A2—lymph node—lung cancer	0.000303	0.0131	CbGeAlD
Amphetamine—Benzyl alcohol—CYP2E1—lung cancer	0.000266	0.0776	CrCbGaD
Amphetamine—Benzyl alcohol—CYP1A1—lung cancer	0.000262	0.0766	CrCbGaD
Amphetamine—Anorexia—Irinotecan—lung cancer	0.000261	0.00159	CcSEcCtD
Amphetamine—Anxiety—Cisplatin—lung cancer	0.000258	0.00157	CcSEcCtD
Amphetamine—Hyperhidrosis—Gemcitabine—lung cancer	0.000258	0.00157	CcSEcCtD
Amphetamine—SLC22A5—lymph node—lung cancer	0.000257	0.0111	CbGeAlD
Amphetamine—Dizziness—Topotecan—lung cancer	0.000256	0.00156	CcSEcCtD
Amphetamine—Tremor—Paclitaxel—lung cancer	0.000256	0.00156	CcSEcCtD
Amphetamine—Selegiline—CYP2E1—lung cancer	0.000255	0.0745	CrCbGaD
Amphetamine—Anorexia—Gemcitabine—lung cancer	0.000254	0.00154	CcSEcCtD
Amphetamine—Vomiting—Vinblastine—lung cancer	0.000254	0.00154	CcSEcCtD
Amphetamine—Dizziness—Erlotinib—lung cancer	0.000254	0.00154	CcSEcCtD
Amphetamine—Erythema multiforme—Docetaxel—lung cancer	0.000252	0.00153	CcSEcCtD
Amphetamine—Agitation—Paclitaxel—lung cancer	0.000251	0.00153	CcSEcCtD
Amphetamine—Headache—Vinblastine—lung cancer	0.00025	0.00152	CcSEcCtD
Amphetamine—Angioedema—Paclitaxel—lung cancer	0.00025	0.00152	CcSEcCtD
Amphetamine—Toxic epidermal necrolysis—Methotrexate—lung cancer	0.00025	0.00152	CcSEcCtD
Amphetamine—Anaphylactic shock—Cisplatin—lung cancer	0.000248	0.00151	CcSEcCtD
Amphetamine—Insomnia—Irinotecan—lung cancer	0.000247	0.0015	CcSEcCtD
Amphetamine—Infection—Cisplatin—lung cancer	0.000247	0.0015	CcSEcCtD
Amphetamine—Vomiting—Topotecan—lung cancer	0.000246	0.0015	CcSEcCtD
Amphetamine—Cerebrovascular accident—Doxorubicin—lung cancer	0.000245	0.00149	CcSEcCtD
Amphetamine—Rash—Topotecan—lung cancer	0.000244	0.00149	CcSEcCtD
Amphetamine—Hypersensitivity—Vinorelbine—lung cancer	0.000244	0.00149	CcSEcCtD
Amphetamine—Dermatitis—Topotecan—lung cancer	0.000244	0.00149	CcSEcCtD
Amphetamine—Vomiting—Erlotinib—lung cancer	0.000244	0.00148	CcSEcCtD
Amphetamine—Dyspnoea—Irinotecan—lung cancer	0.000244	0.00148	CcSEcCtD
Amphetamine—Somnolence—Irinotecan—lung cancer	0.000243	0.00148	CcSEcCtD
Amphetamine—Headache—Topotecan—lung cancer	0.000243	0.00148	CcSEcCtD
Amphetamine—Tachycardia—Cisplatin—lung cancer	0.000242	0.00147	CcSEcCtD
Amphetamine—Rash—Erlotinib—lung cancer	0.000242	0.00147	CcSEcCtD
Amphetamine—Dermatitis—Erlotinib—lung cancer	0.000242	0.00147	CcSEcCtD
Amphetamine—Palpitations—Paclitaxel—lung cancer	0.000242	0.00147	CcSEcCtD
Amphetamine—Convulsion—Etoposide—lung cancer	0.000242	0.00147	CcSEcCtD
Amphetamine—Insomnia—Gemcitabine—lung cancer	0.000241	0.00147	CcSEcCtD
Amphetamine—Dyspepsia—Irinotecan—lung cancer	0.000241	0.00146	CcSEcCtD
Amphetamine—Hypertension—Etoposide—lung cancer	0.000241	0.00146	CcSEcCtD
Amphetamine—Headache—Erlotinib—lung cancer	0.00024	0.00146	CcSEcCtD
Amphetamine—Hyperhidrosis—Cisplatin—lung cancer	0.00024	0.00146	CcSEcCtD
Amphetamine—Asthenia—Vinorelbine—lung cancer	0.000238	0.00145	CcSEcCtD
Amphetamine—Decreased appetite—Irinotecan—lung cancer	0.000238	0.00145	CcSEcCtD
Amphetamine—Dyspnoea—Gemcitabine—lung cancer	0.000238	0.00144	CcSEcCtD
Amphetamine—Chest pain—Etoposide—lung cancer	0.000237	0.00144	CcSEcCtD
Amphetamine—Nausea—Vinblastine—lung cancer	0.000237	0.00144	CcSEcCtD
Amphetamine—Somnolence—Gemcitabine—lung cancer	0.000237	0.00144	CcSEcCtD
Amphetamine—Convulsion—Paclitaxel—lung cancer	0.000237	0.00144	CcSEcCtD
Amphetamine—Anorexia—Cisplatin—lung cancer	0.000237	0.00144	CcSEcCtD
Amphetamine—Affect lability—Doxorubicin—lung cancer	0.000236	0.00144	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Irinotecan—lung cancer	0.000236	0.00144	CcSEcCtD
Amphetamine—Hypertension—Paclitaxel—lung cancer	0.000236	0.00144	CcSEcCtD
Amphetamine—Fatigue—Irinotecan—lung cancer	0.000236	0.00143	CcSEcCtD
Amphetamine—Constipation—Irinotecan—lung cancer	0.000234	0.00142	CcSEcCtD
Amphetamine—Chest pain—Paclitaxel—lung cancer	0.000233	0.00142	CcSEcCtD
Amphetamine—Anxiety—Paclitaxel—lung cancer	0.000232	0.00141	CcSEcCtD
Amphetamine—Decreased appetite—Gemcitabine—lung cancer	0.000232	0.00141	CcSEcCtD
Amphetamine—Nausea—Topotecan—lung cancer	0.00023	0.0014	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Gemcitabine—lung cancer	0.00023	0.0014	CcSEcCtD
Amphetamine—Fatigue—Gemcitabine—lung cancer	0.00023	0.0014	CcSEcCtD
Amphetamine—Constipation—Gemcitabine—lung cancer	0.000228	0.00139	CcSEcCtD
Amphetamine—Nausea—Erlotinib—lung cancer	0.000228	0.00139	CcSEcCtD
Amphetamine—Dry mouth—Paclitaxel—lung cancer	0.000228	0.00138	CcSEcCtD
Amphetamine—Anaphylactic shock—Etoposide—lung cancer	0.000227	0.00138	CcSEcCtD
Amphetamine—Mood swings—Doxorubicin—lung cancer	0.000227	0.00138	CcSEcCtD
Amphetamine—Diarrhoea—Vinorelbine—lung cancer	0.000227	0.00138	CcSEcCtD
Amphetamine—Infection—Etoposide—lung cancer	0.000226	0.00137	CcSEcCtD
Amphetamine—Phenelzine—CYP2E1—lung cancer	0.000225	0.0656	CrCbGaD
Amphetamine—Gastrointestinal pain—Irinotecan—lung cancer	0.000224	0.00136	CcSEcCtD
Amphetamine—Anaphylactic shock—Paclitaxel—lung cancer	0.000223	0.00136	CcSEcCtD
Amphetamine—Tachycardia—Etoposide—lung cancer	0.000222	0.00135	CcSEcCtD
Amphetamine—Infection—Paclitaxel—lung cancer	0.000222	0.00135	CcSEcCtD
Amphetamine—Dyspnoea—Cisplatin—lung cancer	0.000221	0.00135	CcSEcCtD
Amphetamine—Erectile dysfunction—Methotrexate—lung cancer	0.000221	0.00134	CcSEcCtD
Amphetamine—Hyperhidrosis—Etoposide—lung cancer	0.00022	0.00134	CcSEcCtD
Amphetamine—Dizziness—Vinorelbine—lung cancer	0.000219	0.00133	CcSEcCtD
Amphetamine—Abdominal pain upper—Doxorubicin—lung cancer	0.000219	0.00133	CcSEcCtD
Amphetamine—Photosensitivity reaction—Methotrexate—lung cancer	0.000219	0.00133	CcSEcCtD
Amphetamine—Tachycardia—Paclitaxel—lung cancer	0.000218	0.00132	CcSEcCtD
Amphetamine—Anorexia—Etoposide—lung cancer	0.000217	0.00132	CcSEcCtD
Amphetamine—Abdominal pain—Irinotecan—lung cancer	0.000216	0.00131	CcSEcCtD
Amphetamine—Body temperature increased—Irinotecan—lung cancer	0.000216	0.00131	CcSEcCtD
Amphetamine—Toxic epidermal necrolysis—Doxorubicin—lung cancer	0.000216	0.00131	CcSEcCtD
Amphetamine—Decreased appetite—Cisplatin—lung cancer	0.000216	0.00131	CcSEcCtD
Amphetamine—Hyperhidrosis—Paclitaxel—lung cancer	0.000216	0.00131	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Cisplatin—lung cancer	0.000214	0.0013	CcSEcCtD
Amphetamine—Depression—Methotrexate—lung cancer	0.000213	0.0013	CcSEcCtD
Amphetamine—Anorexia—Paclitaxel—lung cancer	0.000213	0.00129	CcSEcCtD
Amphetamine—Stevens-Johnson syndrome—Methotrexate—lung cancer	0.000212	0.00129	CcSEcCtD
Amphetamine—Vomiting—Vinorelbine—lung cancer	0.000211	0.00128	CcSEcCtD
Amphetamine—Body temperature increased—Gemcitabine—lung cancer	0.000211	0.00128	CcSEcCtD
Amphetamine—Rash—Vinorelbine—lung cancer	0.000209	0.00127	CcSEcCtD
Amphetamine—Dermatitis—Vinorelbine—lung cancer	0.000209	0.00127	CcSEcCtD
Amphetamine—Headache—Vinorelbine—lung cancer	0.000208	0.00126	CcSEcCtD
Amphetamine—Sweating—Methotrexate—lung cancer	0.000205	0.00125	CcSEcCtD
Amphetamine—Palpitations—Docetaxel—lung cancer	0.000205	0.00125	CcSEcCtD
Amphetamine—Dyspnoea—Etoposide—lung cancer	0.000203	0.00123	CcSEcCtD
Amphetamine—Somnolence—Etoposide—lung cancer	0.000202	0.00123	CcSEcCtD
Amphetamine—Insomnia—Paclitaxel—lung cancer	0.000202	0.00123	CcSEcCtD
Amphetamine—Hypersensitivity—Irinotecan—lung cancer	0.000202	0.00123	CcSEcCtD
Amphetamine—Convulsion—Docetaxel—lung cancer	0.000201	0.00122	CcSEcCtD
Amphetamine—Hypertension—Docetaxel—lung cancer	0.0002	0.00122	CcSEcCtD
Amphetamine—Dyspnoea—Paclitaxel—lung cancer	0.000199	0.00121	CcSEcCtD
Amphetamine—Somnolence—Paclitaxel—lung cancer	0.000198	0.00121	CcSEcCtD
Amphetamine—Decreased appetite—Etoposide—lung cancer	0.000198	0.0012	CcSEcCtD
Amphetamine—Chest pain—Docetaxel—lung cancer	0.000197	0.0012	CcSEcCtD
Amphetamine—Nausea—Vinorelbine—lung cancer	0.000197	0.0012	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Etoposide—lung cancer	0.000196	0.00119	CcSEcCtD
Amphetamine—Dyspepsia—Paclitaxel—lung cancer	0.000196	0.00119	CcSEcCtD
Amphetamine—Body temperature increased—Cisplatin—lung cancer	0.000196	0.00119	CcSEcCtD
Amphetamine—Asthenia—Irinotecan—lung cancer	0.000196	0.00119	CcSEcCtD
Amphetamine—Fatigue—Etoposide—lung cancer	0.000196	0.00119	CcSEcCtD
Amphetamine—Constipation—Etoposide—lung cancer	0.000195	0.00118	CcSEcCtD
Amphetamine—Decreased appetite—Paclitaxel—lung cancer	0.000194	0.00118	CcSEcCtD
Amphetamine—Dry mouth—Docetaxel—lung cancer	0.000193	0.00117	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Paclitaxel—lung cancer	0.000193	0.00117	CcSEcCtD
Amphetamine—Fatigue—Paclitaxel—lung cancer	0.000192	0.00117	CcSEcCtD
Amphetamine—Asthenia—Gemcitabine—lung cancer	0.000191	0.00116	CcSEcCtD
Amphetamine—Constipation—Paclitaxel—lung cancer	0.000191	0.00116	CcSEcCtD
Amphetamine—Photosensitivity reaction—Doxorubicin—lung cancer	0.000189	0.00115	CcSEcCtD
Amphetamine—Anaphylactic shock—Docetaxel—lung cancer	0.000189	0.00115	CcSEcCtD
Amphetamine—Infection—Docetaxel—lung cancer	0.000188	0.00114	CcSEcCtD
Amphetamine—Weight decreased—Doxorubicin—lung cancer	0.000188	0.00114	CcSEcCtD
Amphetamine—Diarrhoea—Irinotecan—lung cancer	0.000187	0.00114	CcSEcCtD
Amphetamine—Gastrointestinal pain—Etoposide—lung cancer	0.000186	0.00113	CcSEcCtD
Amphetamine—Tachycardia—Docetaxel—lung cancer	0.000185	0.00112	CcSEcCtD
Amphetamine—Stevens-Johnson syndrome—Doxorubicin—lung cancer	0.000183	0.00112	CcSEcCtD
Amphetamine—Hypersensitivity—Cisplatin—lung cancer	0.000183	0.00111	CcSEcCtD
Amphetamine—Gastrointestinal pain—Paclitaxel—lung cancer	0.000182	0.00111	CcSEcCtD
Amphetamine—Diarrhoea—Gemcitabine—lung cancer	0.000182	0.00111	CcSEcCtD
Amphetamine—Erythema multiforme—Methotrexate—lung cancer	0.000181	0.0011	CcSEcCtD
Amphetamine—Dizziness—Irinotecan—lung cancer	0.000181	0.0011	CcSEcCtD
Amphetamine—Urticaria—Etoposide—lung cancer	0.000181	0.0011	CcSEcCtD
Amphetamine—Anorexia—Docetaxel—lung cancer	0.00018	0.0011	CcSEcCtD
Amphetamine—Abdominal pain—Etoposide—lung cancer	0.00018	0.00109	CcSEcCtD
Amphetamine—Body temperature increased—Etoposide—lung cancer	0.00018	0.00109	CcSEcCtD
Amphetamine—Urinary tract infection—Doxorubicin—lung cancer	0.00018	0.00109	CcSEcCtD
Amphetamine—Asthenia—Cisplatin—lung cancer	0.000178	0.00108	CcSEcCtD
Amphetamine—Sweating—Doxorubicin—lung cancer	0.000177	0.00108	CcSEcCtD
Amphetamine—Urticaria—Paclitaxel—lung cancer	0.000177	0.00108	CcSEcCtD
Amphetamine—Body temperature increased—Paclitaxel—lung cancer	0.000176	0.00107	CcSEcCtD
Amphetamine—Abdominal pain—Paclitaxel—lung cancer	0.000176	0.00107	CcSEcCtD
Amphetamine—Vomiting—Irinotecan—lung cancer	0.000174	0.00106	CcSEcCtD
Amphetamine—Rash—Irinotecan—lung cancer	0.000172	0.00105	CcSEcCtD
Amphetamine—Dermatitis—Irinotecan—lung cancer	0.000172	0.00105	CcSEcCtD
Amphetamine—Headache—Irinotecan—lung cancer	0.000171	0.00104	CcSEcCtD
Amphetamine—Insomnia—Docetaxel—lung cancer	0.000171	0.00104	CcSEcCtD
Amphetamine—Diarrhoea—Cisplatin—lung cancer	0.00017	0.00103	CcSEcCtD
Amphetamine—Vomiting—Gemcitabine—lung cancer	0.000169	0.00103	CcSEcCtD
Amphetamine—Dyspnoea—Docetaxel—lung cancer	0.000169	0.00103	CcSEcCtD
Amphetamine—Somnolence—Docetaxel—lung cancer	0.000168	0.00102	CcSEcCtD
Amphetamine—Rash—Gemcitabine—lung cancer	0.000168	0.00102	CcSEcCtD
Amphetamine—Dermatitis—Gemcitabine—lung cancer	0.000168	0.00102	CcSEcCtD
Amphetamine—Hypersensitivity—Etoposide—lung cancer	0.000168	0.00102	CcSEcCtD
Amphetamine—Headache—Gemcitabine—lung cancer	0.000167	0.00102	CcSEcCtD
Amphetamine—Dyspepsia—Docetaxel—lung cancer	0.000166	0.00101	CcSEcCtD
Amphetamine—Decreased appetite—Docetaxel—lung cancer	0.000164	0.001	CcSEcCtD
Amphetamine—Hypersensitivity—Paclitaxel—lung cancer	0.000164	0.001	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Docetaxel—lung cancer	0.000163	0.000993	CcSEcCtD
Amphetamine—Asthenia—Etoposide—lung cancer	0.000163	0.000993	CcSEcCtD
Amphetamine—Fatigue—Docetaxel—lung cancer	0.000163	0.000991	CcSEcCtD
Amphetamine—Nausea—Irinotecan—lung cancer	0.000162	0.000988	CcSEcCtD
Amphetamine—Constipation—Docetaxel—lung cancer	0.000162	0.000983	CcSEcCtD
Amphetamine—Asthenia—Paclitaxel—lung cancer	0.00016	0.000973	CcSEcCtD
Amphetamine—Nausea—Gemcitabine—lung cancer	0.000158	0.000962	CcSEcCtD
Amphetamine—Vomiting—Cisplatin—lung cancer	0.000158	0.00096	CcSEcCtD
Amphetamine—Erythema multiforme—Doxorubicin—lung cancer	0.000157	0.000955	CcSEcCtD
Amphetamine—Rash—Cisplatin—lung cancer	0.000157	0.000952	CcSEcCtD
Amphetamine—Dermatitis—Cisplatin—lung cancer	0.000156	0.000951	CcSEcCtD
Amphetamine—Diarrhoea—Etoposide—lung cancer	0.000156	0.000947	CcSEcCtD
Amphetamine—Gastrointestinal pain—Docetaxel—lung cancer	0.000155	0.00094	CcSEcCtD
Amphetamine—Diarrhoea—Paclitaxel—lung cancer	0.000153	0.000928	CcSEcCtD
Amphetamine—Dizziness—Etoposide—lung cancer	0.00015	0.000915	CcSEcCtD
Amphetamine—Abdominal pain—Docetaxel—lung cancer	0.000149	0.000909	CcSEcCtD
Amphetamine—Body temperature increased—Docetaxel—lung cancer	0.000149	0.000909	CcSEcCtD
Amphetamine—Dizziness—Paclitaxel—lung cancer	0.000148	0.000897	CcSEcCtD
Amphetamine—Nausea—Cisplatin—lung cancer	0.000147	0.000897	CcSEcCtD
Amphetamine—Convulsion—Methotrexate—lung cancer	0.000145	0.00088	CcSEcCtD
Amphetamine—Vomiting—Etoposide—lung cancer	0.000145	0.00088	CcSEcCtD
Amphetamine—Rash—Etoposide—lung cancer	0.000143	0.000872	CcSEcCtD
Amphetamine—Dermatitis—Etoposide—lung cancer	0.000143	0.000872	CcSEcCtD
Amphetamine—Headache—Etoposide—lung cancer	0.000143	0.000867	CcSEcCtD
Amphetamine—Chest pain—Methotrexate—lung cancer	0.000142	0.000865	CcSEcCtD
Amphetamine—Tension—Doxorubicin—lung cancer	0.000142	0.000863	CcSEcCtD
Amphetamine—Vomiting—Paclitaxel—lung cancer	0.000142	0.000863	CcSEcCtD
Amphetamine—Rash—Paclitaxel—lung cancer	0.000141	0.000855	CcSEcCtD
Amphetamine—Dermatitis—Paclitaxel—lung cancer	0.000141	0.000855	CcSEcCtD
Amphetamine—Nervousness—Doxorubicin—lung cancer	0.00014	0.000854	CcSEcCtD
Amphetamine—Headache—Paclitaxel—lung cancer	0.00014	0.00085	CcSEcCtD
Amphetamine—Hypersensitivity—Docetaxel—lung cancer	0.000139	0.000847	CcSEcCtD
Amphetamine—Anaphylactic shock—Methotrexate—lung cancer	0.000136	0.000829	CcSEcCtD
Amphetamine—Asthenia—Docetaxel—lung cancer	0.000136	0.000825	CcSEcCtD
Amphetamine—Infection—Methotrexate—lung cancer	0.000135	0.000823	CcSEcCtD
Amphetamine—Nausea—Etoposide—lung cancer	0.000135	0.000822	CcSEcCtD
Amphetamine—Selegiline—ABCB1—lung cancer	0.000134	0.0391	CrCbGaD
Amphetamine—Agitation—Doxorubicin—lung cancer	0.000133	0.000808	CcSEcCtD
Amphetamine—Nausea—Paclitaxel—lung cancer	0.000132	0.000806	CcSEcCtD
Amphetamine—Hyperhidrosis—Methotrexate—lung cancer	0.000132	0.000801	CcSEcCtD
Amphetamine—Anorexia—Methotrexate—lung cancer	0.00013	0.00079	CcSEcCtD
Amphetamine—Diarrhoea—Docetaxel—lung cancer	0.000129	0.000787	CcSEcCtD
Amphetamine—Palpitations—Doxorubicin—lung cancer	0.000128	0.000777	CcSEcCtD
Amphetamine—Nateglinide—ALB—lung cancer	0.000125	0.0366	CrCbGaD
Amphetamine—Convulsion—Doxorubicin—lung cancer	0.000125	0.000762	CcSEcCtD
Amphetamine—Dizziness—Docetaxel—lung cancer	0.000125	0.00076	CcSEcCtD
Amphetamine—Hypertension—Doxorubicin—lung cancer	0.000125	0.000759	CcSEcCtD
Amphetamine—Insomnia—Methotrexate—lung cancer	0.000123	0.00075	CcSEcCtD
Amphetamine—Chest pain—Doxorubicin—lung cancer	0.000123	0.000749	CcSEcCtD
Amphetamine—Anxiety—Doxorubicin—lung cancer	0.000123	0.000746	CcSEcCtD
Amphetamine—Dyspnoea—Methotrexate—lung cancer	0.000121	0.000739	CcSEcCtD
Amphetamine—Somnolence—Methotrexate—lung cancer	0.000121	0.000737	CcSEcCtD
Amphetamine—Dry mouth—Doxorubicin—lung cancer	0.00012	0.000732	CcSEcCtD
Amphetamine—Vomiting—Docetaxel—lung cancer	0.00012	0.000731	CcSEcCtD
Amphetamine—Dyspepsia—Methotrexate—lung cancer	0.00012	0.00073	CcSEcCtD
Amphetamine—Rash—Docetaxel—lung cancer	0.000119	0.000725	CcSEcCtD
Amphetamine—Dermatitis—Docetaxel—lung cancer	0.000119	0.000724	CcSEcCtD
Amphetamine—Decreased appetite—Methotrexate—lung cancer	0.000118	0.00072	CcSEcCtD
Amphetamine—Headache—Docetaxel—lung cancer	0.000118	0.00072	CcSEcCtD
Amphetamine—Anaphylactic shock—Doxorubicin—lung cancer	0.000118	0.000718	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Methotrexate—lung cancer	0.000118	0.000716	CcSEcCtD
Amphetamine—Fatigue—Methotrexate—lung cancer	0.000117	0.000715	CcSEcCtD
Amphetamine—Infection—Doxorubicin—lung cancer	0.000117	0.000713	CcSEcCtD
Amphetamine—Tachycardia—Doxorubicin—lung cancer	0.000115	0.0007	CcSEcCtD
Amphetamine—Hyperhidrosis—Doxorubicin—lung cancer	0.000114	0.000694	CcSEcCtD
Amphetamine—Anorexia—Doxorubicin—lung cancer	0.000112	0.000684	CcSEcCtD
Amphetamine—Nausea—Docetaxel—lung cancer	0.000112	0.000683	CcSEcCtD
Amphetamine—Gastrointestinal pain—Methotrexate—lung cancer	0.000111	0.000678	CcSEcCtD
Amphetamine—Urticaria—Methotrexate—lung cancer	0.000108	0.000658	CcSEcCtD
Amphetamine—Body temperature increased—Methotrexate—lung cancer	0.000108	0.000655	CcSEcCtD
Amphetamine—Abdominal pain—Methotrexate—lung cancer	0.000108	0.000655	CcSEcCtD
Amphetamine—Insomnia—Doxorubicin—lung cancer	0.000107	0.000649	CcSEcCtD
Amphetamine—Dyspnoea—Doxorubicin—lung cancer	0.000105	0.00064	CcSEcCtD
Amphetamine—Somnolence—Doxorubicin—lung cancer	0.000105	0.000638	CcSEcCtD
Amphetamine—Dyspepsia—Doxorubicin—lung cancer	0.000104	0.000632	CcSEcCtD
Amphetamine—Decreased appetite—Doxorubicin—lung cancer	0.000103	0.000624	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Doxorubicin—lung cancer	0.000102	0.00062	CcSEcCtD
Amphetamine—Fatigue—Doxorubicin—lung cancer	0.000102	0.000619	CcSEcCtD
Amphetamine—Constipation—Doxorubicin—lung cancer	0.000101	0.000614	CcSEcCtD
Amphetamine—Hypersensitivity—Methotrexate—lung cancer	0.0001	0.000611	CcSEcCtD
Amphetamine—Asthenia—Methotrexate—lung cancer	9.78e-05	0.000595	CcSEcCtD
Amphetamine—Gastrointestinal pain—Doxorubicin—lung cancer	9.65e-05	0.000587	CcSEcCtD
Amphetamine—Urticaria—Doxorubicin—lung cancer	9.37e-05	0.00057	CcSEcCtD
Amphetamine—Body temperature increased—Doxorubicin—lung cancer	9.33e-05	0.000567	CcSEcCtD
Amphetamine—Abdominal pain—Doxorubicin—lung cancer	9.33e-05	0.000567	CcSEcCtD
Amphetamine—Diarrhoea—Methotrexate—lung cancer	9.32e-05	0.000567	CcSEcCtD
Amphetamine—Dizziness—Methotrexate—lung cancer	9.01e-05	0.000548	CcSEcCtD
Amphetamine—Hypersensitivity—Doxorubicin—lung cancer	8.69e-05	0.000529	CcSEcCtD
Amphetamine—Vomiting—Methotrexate—lung cancer	8.66e-05	0.000527	CcSEcCtD
Amphetamine—Rash—Methotrexate—lung cancer	8.59e-05	0.000523	CcSEcCtD
Amphetamine—Dermatitis—Methotrexate—lung cancer	8.58e-05	0.000522	CcSEcCtD
Amphetamine—Headache—Methotrexate—lung cancer	8.54e-05	0.000519	CcSEcCtD
Amphetamine—Asthenia—Doxorubicin—lung cancer	8.47e-05	0.000515	CcSEcCtD
Amphetamine—Nausea—Methotrexate—lung cancer	8.09e-05	0.000492	CcSEcCtD
Amphetamine—Diarrhoea—Doxorubicin—lung cancer	8.07e-05	0.000491	CcSEcCtD
Amphetamine—Dizziness—Doxorubicin—lung cancer	7.8e-05	0.000475	CcSEcCtD
Amphetamine—Vomiting—Doxorubicin—lung cancer	7.5e-05	0.000456	CcSEcCtD
Amphetamine—Rash—Doxorubicin—lung cancer	7.44e-05	0.000452	CcSEcCtD
Amphetamine—Dermatitis—Doxorubicin—lung cancer	7.43e-05	0.000452	CcSEcCtD
Amphetamine—Headache—Doxorubicin—lung cancer	7.39e-05	0.00045	CcSEcCtD
Amphetamine—Nausea—Doxorubicin—lung cancer	7.01e-05	0.000426	CcSEcCtD
Amphetamine—MAOB—Metabolism—CYP1A1—lung cancer	2.16e-05	0.000148	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—ERCC2—lung cancer	2.14e-05	0.000147	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—GRM8—lung cancer	2.13e-05	0.000146	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL8—lung cancer	2.12e-05	0.000145	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—UGT1A1—lung cancer	2.12e-05	0.000145	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—HSD17B10—lung cancer	2.11e-05	0.000144	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—GSTP1—lung cancer	2.1e-05	0.000144	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CXCL8—lung cancer	2.09e-05	0.000144	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—POMC—lung cancer	2.08e-05	0.000143	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—HRAS—lung cancer	2.08e-05	0.000143	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—APP—lung cancer	2.07e-05	0.000142	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—ALB—lung cancer	2.07e-05	0.000142	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—SKI—lung cancer	2.06e-05	0.000141	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—CAT—lung cancer	2.04e-05	0.00014	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—GNG11—lung cancer	2.04e-05	0.00014	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—AKT1—lung cancer	2.02e-05	0.000139	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CASP3—lung cancer	2e-05	0.000137	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—IL2—lung cancer	2e-05	0.000137	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—IL6—lung cancer	1.99e-05	0.000137	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—ABCB1—lung cancer	1.99e-05	0.000136	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CKB—lung cancer	1.96e-05	0.000134	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—CREBBP—lung cancer	1.96e-05	0.000134	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—TYMS—lung cancer	1.95e-05	0.000134	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CCND1—lung cancer	1.95e-05	0.000134	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—JUN—lung cancer	1.95e-05	0.000133	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ALDOA—lung cancer	1.94e-05	0.000133	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—GSTM1—lung cancer	1.93e-05	0.000132	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—MMP9—lung cancer	1.89e-05	0.00013	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CDKN1A—lung cancer	1.89e-05	0.000129	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—NCOA3—lung cancer	1.89e-05	0.000129	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—PTEN—lung cancer	1.88e-05	0.000129	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—RAF1—lung cancer	1.87e-05	0.000128	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—APOA1—lung cancer	1.86e-05	0.000127	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—TP53—lung cancer	1.85e-05	0.000127	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CNDP2—lung cancer	1.84e-05	0.000126	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GSTM2—lung cancer	1.84e-05	0.000126	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—AKT1—lung cancer	1.84e-05	0.000126	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ADCY1—lung cancer	1.83e-05	0.000126	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ABCG2—lung cancer	1.83e-05	0.000126	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—ALB—lung cancer	1.83e-05	0.000125	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—CYP1A1—lung cancer	1.83e-05	0.000125	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—ERCC2—lung cancer	1.81e-05	0.000124	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—HPGDS—lung cancer	1.8e-05	0.000123	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ENO2—lung cancer	1.8e-05	0.000123	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—EP300—lung cancer	1.8e-05	0.000123	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—MTMR3—lung cancer	1.79e-05	0.000123	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PXN—lung cancer	1.79e-05	0.000123	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PPP2R1B—lung cancer	1.79e-05	0.000123	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—AVP—lung cancer	1.77e-05	0.000121	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—OXTR—lung cancer	1.75e-05	0.00012	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—AKR1C1—lung cancer	1.75e-05	0.00012	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—GRP—lung cancer	1.75e-05	0.00012	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—SRC—lung cancer	1.75e-05	0.00012	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PGAM1—lung cancer	1.75e-05	0.00012	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—GSTT1—lung cancer	1.74e-05	0.00012	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—GCLC—lung cancer	1.72e-05	0.000118	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—VEGFA—lung cancer	1.7e-05	0.000117	CbGpPWpGaD
Amphetamine—SLC6A3—Neuronal System—HRAS—lung cancer	1.7e-05	0.000116	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PIK3CG—lung cancer	1.69e-05	0.000116	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—IL6—lung cancer	1.69e-05	0.000116	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—STAT3—lung cancer	1.68e-05	0.000115	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—NRAS—lung cancer	1.68e-05	0.000115	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CYP2A7—lung cancer	1.66e-05	0.000114	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—RAF1—lung cancer	1.66e-05	0.000113	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—GNG11—lung cancer	1.64e-05	0.000112	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ENO1—lung cancer	1.63e-05	0.000112	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—SDC4—lung cancer	1.63e-05	0.000112	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—POMC—lung cancer	1.61e-05	0.000111	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—CXCL8—lung cancer	1.61e-05	0.00011	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—MAPK3—lung cancer	1.61e-05	0.00011	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—AVP—lung cancer	1.61e-05	0.00011	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—CREBBP—lung cancer	1.57e-05	0.000108	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—APOA1—lung cancer	1.57e-05	0.000108	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—MYC—lung cancer	1.57e-05	0.000107	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—VEGFC—lung cancer	1.56e-05	0.000107	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—EGFR—lung cancer	1.53e-05	0.000105	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PIK3CD—lung cancer	1.49e-05	0.000102	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—RRM1—lung cancer	1.48e-05	0.000102	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GSTA3—lung cancer	1.48e-05	0.000102	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—ADCY1—lung cancer	1.47e-05	0.000101	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—ALB—lung cancer	1.47e-05	0.000101	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CYP2E1—lung cancer	1.47e-05	0.000101	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—NQO1—lung cancer	1.45e-05	9.94e-05	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—KRAS—lung cancer	1.45e-05	9.91e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—SMARCA4—lung cancer	1.44e-05	9.85e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PPP2R1B—lung cancer	1.44e-05	9.85e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PIK3CG—lung cancer	1.43e-05	9.82e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—B4GALT5—lung cancer	1.4e-05	9.56e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—HSPB1—lung cancer	1.39e-05	9.5e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PTHLH—lung cancer	1.37e-05	9.4e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—POMC—lung cancer	1.36e-05	9.35e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GSTA4—lung cancer	1.36e-05	9.3e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—CREBBP—lung cancer	1.33e-05	9.11e-05	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—PIK3CA—lung cancer	1.33e-05	9.11e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GSTA2—lung cancer	1.32e-05	9.07e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—STK11—lung cancer	1.31e-05	8.96e-05	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PIK3CB—lung cancer	1.3e-05	8.9e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—ANXA1—lung cancer	1.29e-05	8.83e-05	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PTGS2—lung cancer	1.29e-05	8.82e-05	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—TP53—lung cancer	1.29e-05	8.81e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GSTA1—lung cancer	1.28e-05	8.75e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ABCC3—lung cancer	1.26e-05	8.65e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PIK3CD—lung cancer	1.26e-05	8.64e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—FLT1—lung cancer	1.25e-05	8.56e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—ALB—lung cancer	1.24e-05	8.53e-05	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—PIK3CG—lung cancer	1.24e-05	8.48e-05	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—HRAS—lung cancer	1.23e-05	8.43e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—AKR1C1—lung cancer	1.22e-05	8.38e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—APP—lung cancer	1.22e-05	8.38e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—NOTCH3—lung cancer	1.22e-05	8.38e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—FGF9—lung cancer	1.21e-05	8.31e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—GSTP1—lung cancer	1.21e-05	8.29e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—UGT1A1—lung cancer	1.19e-05	8.13e-05	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—POMC—lung cancer	1.18e-05	8.07e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CAT—lung cancer	1.18e-05	8.07e-05	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—IL6—lung cancer	1.18e-05	8.06e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—JUNB—lung cancer	1.16e-05	7.93e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ABCB1—lung cancer	1.14e-05	7.85e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GNG11—lung cancer	1.14e-05	7.84e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—TYMS—lung cancer	1.12e-05	7.71e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—PIK3CG—lung cancer	1.12e-05	7.7e-05	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PTEN—lung cancer	1.12e-05	7.69e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—GSTM1—lung cancer	1.11e-05	7.62e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PIK3CB—lung cancer	1.1e-05	7.53e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ALDOA—lung cancer	1.09e-05	7.47e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PTGS2—lung cancer	1.09e-05	7.46e-05	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—PIK3CD—lung cancer	1.09e-05	7.45e-05	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—AKT1—lung cancer	1.09e-05	7.44e-05	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—EP300—lung cancer	1.07e-05	7.33e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—POMC—lung cancer	1.07e-05	7.33e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—NCOA3—lung cancer	1.06e-05	7.25e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CYP1A1—lung cancer	1.05e-05	7.22e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—STK11—lung cancer	1.05e-05	7.2e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ERCC2—lung cancer	1.04e-05	7.16e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—IL6R—lung cancer	1.04e-05	7.15e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ADCY1—lung cancer	1.03e-05	7.05e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ABCG2—lung cancer	1.03e-05	7.05e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—FOXO3—lung cancer	1.01e-05	6.95e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—HPGDS—lung cancer	1.01e-05	6.91e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ENO2—lung cancer	1.01e-05	6.91e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PPP2R1B—lung cancer	1e-05	6.87e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—MAP2K1—lung cancer	9.94e-06	6.81e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—PIK3CD—lung cancer	9.87e-06	6.77e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GSTT1—lung cancer	9.78e-06	6.71e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CYP2A6—lung cancer	9.67e-06	6.63e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GCLC—lung cancer	9.67e-06	6.63e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—AVP—lung cancer	9.5e-06	6.51e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PTEN—lung cancer	9.49e-06	6.5e-05	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—PIK3CB—lung cancer	9.47e-06	6.5e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ENO1—lung cancer	9.17e-06	6.28e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IGF1R—lung cancer	9.15e-06	6.27e-05	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—CXCL8—lung cancer	9.11e-06	6.24e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—EP300—lung cancer	9.05e-06	6.2e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—APOA1—lung cancer	9.04e-06	6.2e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—HES1—lung cancer	8.98e-06	6.16e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—RAF1—lung cancer	8.81e-06	6.04e-05	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—IL2—lung cancer	8.7e-06	5.96e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—PIK3CB—lung cancer	8.6e-06	5.9e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—CXCL8—lung cancer	8.27e-06	5.67e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PIK3CG—lung cancer	8.25e-06	5.66e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CYP2E1—lung cancer	8.22e-06	5.64e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—ERBB3—lung cancer	8.21e-06	5.63e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—NQO1—lung cancer	8.13e-06	5.57e-05	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PIK3CA—lung cancer	7.91e-06	5.42e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—IL2—lung cancer	7.9e-06	5.42e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TERT—lung cancer	7.87e-06	5.4e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—POMC—lung cancer	7.85e-06	5.38e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CREBBP—lung cancer	7.65e-06	5.24e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—FGFR1—lung cancer	7.64e-06	5.24e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—HIF1A—lung cancer	7.53e-06	5.16e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—STK11—lung cancer	7.33e-06	5.02e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—APOA1—lung cancer	7.27e-06	4.98e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PIK3CD—lung cancer	7.25e-06	4.97e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—KDR—lung cancer	7.2e-06	4.94e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ALB—lung cancer	7.16e-06	4.91e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GSTP1—lung cancer	6.78e-06	4.65e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PIK3CA—lung cancer	6.69e-06	4.59e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PIK3CG—lung cancer	6.63e-06	4.55e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—KIT—lung cancer	6.63e-06	4.55e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—APC—lung cancer	6.63e-06	4.55e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—NRAS—lung cancer	6.63e-06	4.55e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CAT—lung cancer	6.6e-06	4.52e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—EGF—lung cancer	6.56e-06	4.49e-05	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—AKT1—lung cancer	6.46e-06	4.43e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ABCB1—lung cancer	6.42e-06	4.4e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—MAPK3—lung cancer	6.35e-06	4.35e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PIK3CB—lung cancer	6.32e-06	4.33e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—POMC—lung cancer	6.31e-06	4.33e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—TYMS—lung cancer	6.3e-06	4.32e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PTGS2—lung cancer	6.27e-06	4.29e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—BRAF—lung cancer	6.24e-06	4.27e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GSTM1—lung cancer	6.23e-06	4.27e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IL6R—lung cancer	6.16e-06	4.22e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CREBBP—lung cancer	6.15e-06	4.22e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—EGFR—lung cancer	6.04e-06	4.14e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CYP1A1—lung cancer	5.91e-06	4.05e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MAP2K1—lung cancer	5.87e-06	4.02e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ERCC2—lung cancer	5.86e-06	4.02e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PIK3CD—lung cancer	5.83e-06	4e-05	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—PIK3CA—lung cancer	5.78e-06	3.96e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—KRAS—lung cancer	5.71e-06	3.91e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—AKT1—lung cancer	5.47e-06	3.75e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PTEN—lung cancer	5.46e-06	3.75e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—PIK3CA—lung cancer	5.25e-06	3.6e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MDM2—lung cancer	5.22e-06	3.58e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—EP300—lung cancer	5.21e-06	3.57e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—RAF1—lung cancer	5.21e-06	3.57e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—ERBB2—lung cancer	5.15e-06	3.53e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MTOR—lung cancer	5.08e-06	3.48e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PIK3CB—lung cancer	5.08e-06	3.48e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—APOA1—lung cancer	5.07e-06	3.47e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CXCL8—lung cancer	4.88e-06	3.35e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—HRAS—lung cancer	4.85e-06	3.33e-05	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—AKT1—lung cancer	4.72e-06	3.23e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CASP3—lung cancer	4.67e-06	3.2e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IL2—lung cancer	4.67e-06	3.2e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—IL6—lung cancer	4.64e-06	3.18e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PIK3CG—lung cancer	4.63e-06	3.17e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CCND1—lung cancer	4.55e-06	3.12e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—JUN—lung cancer	4.54e-06	3.11e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MMP9—lung cancer	4.42e-06	3.03e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—POMC—lung cancer	4.4e-06	3.02e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CDKN1A—lung cancer	4.4e-06	3.02e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PTEN—lung cancer	4.39e-06	3.01e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CREBBP—lung cancer	4.29e-06	2.94e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—AKT1—lung cancer	4.28e-06	2.94e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—EP300—lung cancer	4.19e-06	2.87e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—SRC—lung cancer	4.07e-06	2.79e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PIK3CD—lung cancer	4.07e-06	2.79e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ALB—lung cancer	4.02e-06	2.75e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—VEGFA—lung cancer	3.97e-06	2.72e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—STAT3—lung cancer	3.93e-06	2.69e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—NRAS—lung cancer	3.92e-06	2.69e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PIK3CA—lung cancer	3.85e-06	2.64e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MAPK3—lung cancer	3.75e-06	2.57e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MYC—lung cancer	3.65e-06	2.5e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—EGFR—lung cancer	3.57e-06	2.45e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PIK3CB—lung cancer	3.55e-06	2.43e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PTGS2—lung cancer	3.51e-06	2.41e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—KRAS—lung cancer	3.37e-06	2.31e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—AKT1—lung cancer	3.15e-06	2.16e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PIK3CA—lung cancer	3.1e-06	2.12e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PTEN—lung cancer	3.06e-06	2.1e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TP53—lung cancer	3e-06	2.05e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—EP300—lung cancer	2.92e-06	2e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—HRAS—lung cancer	2.87e-06	1.97e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IL6—lung cancer	2.74e-06	1.88e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—AKT1—lung cancer	2.53e-06	1.74e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PIK3CA—lung cancer	2.16e-06	1.48e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—AKT1—lung cancer	1.77e-06	1.21e-05	CbGpPWpGaD
